Fig. 5 | Scientific Reports

Fig. 5

From: GADD45β inhibits hepatic lipogenesis through the AMPK/SREBP1 pathway via reducing the ubiquitination-mediated degradation of SIRT1

Fig. 5

GADD45β mediated lipogenesis via the SIRT1/AMPK/SREBP1 pathway in hepatocytes. (A) Western blot analysis of p-AMPK, AMPK, and SIRT1 expression in liver tissues from GADD45β-knockdown and control mice (n = 6). (B, C) Representative IHC staining and relative quantification of p-AMPK and SIRT1 in liver sections from the indicated individuals. (n = 6). (D) Western blot of p-AMPK, AMPK, and SIRT1 expression in GADD45β-knockdown HepG2 cells treated with PA (n = 6). (E) Western blot of p-AMPK, AMPK, and SIRT1 expression in GADD45β-overexpressing HepG2 cells treated with PA (n = 6). (F) Western blot analysis of SIRT1 expression in PA-induced HepG2 cells infected with LV-shSIRT1 or LV-shControl. (G) SIRT1, p-AMPK/AMPK, and SREBP-1 expression in PA-induced SIRT1 knockdown and GADD45β-overexpressing HepG2 cells (n = 6). (H) Western blot of p-AMPK/AMPK expression in PA-induced HepG2 cells treated with multiple doses of Compound C. (I) p-AMPK/AMPK and SREBP-1 expression in PA-induced GADD45β-overexpressing and Compound C-treated HepG2 cells (n = 6).

Back to article page